房间隔瘤与分流大小和卒中复发及卵圆孔未闭封堵获益的关联
该研究汇总6项随机临床试验的3740例卵圆孔未闭相关卒中患者个体数据,评估按分流大小和房间隔瘤分组的封堵治疗与卒中复发关联。封堵治疗与复发缺血性卒中风险降低相关(aHR 0.41),同时有大分流和房间隔瘤者获益最大(aHR 0.15),交互作用P=0.02。
要点
- 卵圆孔未闭封堵治疗与复发缺血性卒中风险降低相关(aHR 0.41,95%CI 0.28-0.60)。
- 同时有大分流和房间隔瘤者封堵获益最大(aHR 0.15,95%CI 0.06-0.35)。
- 2年时大分流合并房间隔瘤者绝对风险降低5.5%,其他3类合计1.0%。
核心结论
- 同时存在大分流和房间隔瘤的患者接受卵圆孔未闭封堵的获益明显大于仅大分流、小分流合并房间隔瘤及两者均无者。
- 这些发现结合其他患者特征可能有助于医患共同决策。
研究设计与样本
- 汇总6项于2000年2月至2017年10月开展的随机临床试验的个体患者数据,比较卵圆孔未闭封堵与药物治疗。
- 纳入北美、欧洲、澳大利亚、巴西和韩国的卵圆孔未闭相关卒中患者,共3740例,平均(SD)年龄45(10)岁,女性1682例(45%)。
- 分析于2022年1月完成。
主要发现
- 中位(IQR)随访57(23.7-63.8)个月期间,共发生121例复发性缺血性卒中。
- 卵圆孔未闭封堵治疗与复发性缺血性卒中风险降低相关(aHR 0.41,95%CI 0.28-0.60;P < .001)。
- 大分流合并房间隔瘤者aHR 0.15(95%CI 0.06-0.35),大分流无房间隔瘤者aHR 0.27(95%CI 0.14-0.56),小分流合并房间隔瘤者aHR 0.36(95%CI 0.17-0.78),小分流无房间隔瘤者aHR 0.68(95%CI 0.41-1.13),交互作用P = .02。
- 2年时,大分流合并房间隔瘤者的绝对风险降低为5.5%(95%CI 2.7-8.3),其他3类合计为1.0%。
临床怎么用
- 作者认为,同时有大分流和房间隔瘤的患者接受卵圆孔未闭封堵的获益明显大于其他3类患者。
- 作者认为,这些发现结合其他患者特征可能有助于医患共同决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Patent Foramen Ovale (PFO)-Associated Stroke Causal Likelihood classification system combines information regarding noncardiac patient features (vascular risk factors, infarct topography) and PFO features (shunt size and presence of atrial septal aneurysm [ASA]) to classify patients into 3 validated categories of responsiveness to treatment with PFO closure. However, the distinctive associations of shunt size and ASA, alone and in combination, have not been completely delineated. OBJECTIVE: To evaluate the association of PFO closure with stroke recurrence according to shunt size and/or the presence of an ASA. DESIGN, SETTING, AND PARTICIPANTS: Pooled individual patient data from 6 randomized clinical trials conducted from February 2000 to October 2017 that compared PFO closure with medical therapy. Patients in North America, Europe, Australia, Brazil, and South Korea with PFO-associated stroke were included. Analysis was completed in January 2022. EXPOSURES: Transcatheter PFO closure plus antithrombotic therapy vs antithrombotic therapy alone, stratified into 4 groups based on the combination of 2 features: small vs large PFO shunt size and the presence or absence of an ASA. MAIN OUTCOMES AND MEASURES: Recurrent ischemic stroke. RESULTS: A total of 121 recurrent ischemic strokes occurred in the pooled 3740 patients (mean [SD] age, 45 [10] years; 1682 [45%] female) during a median (IQR) follow-up of 57 (23.7-63.8) months. Treatment with PFO closure was associated with reduced risk for recurrent ischemic stroke (adjusted hazard ratio [aHR], 0.41 [95% CI, 0.28-0.60]; P < .001). The reduction in hazard for recurrent stroke was greater for patients with both a large shunt and an ASA (aHR, 0.15 [95% CI, 0.06-0.35]) than for large shunt without ASA (aHR, 0.27 [95% CI, 0.14-0.56]), small shunt with ASA (aHR, 0.36 [95% CI, 0.17-0.78]), and small shunt without ASA (aHR, 0.68 [95% CI, 0.41-1.13]) (interaction P = .02). At 2 years, the absolute risk reduction of recurrent stroke was greater (5.5% [95% CI, 2.7-8.3]) in patients with large shunt and ASA than for patients in the other 3 categories (1.0% for all). CONCLUSIONS AND RELEVANCE: Patients with both a large shunt and an ASA showed a substantially greater beneficial association with PFO closure than patients with large shunt alone, patients with small shunt and ASA, and patients with neither large shunt nor ASA. These findings, combined with other patient features, may inform shared patient-clinician decision-making.
引用
- Mas JL, Saver JL, Kasner SE, et al. Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure. JAMA Neurol. 2022. PMID: 36215079. doi:10.1001/jamaneurol.2022.3248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。